These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38957800)

  • 1. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility:
    Cequier A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Serrano MB; Zaragoza MP; Romero A; Rodellar C; Barrachina L
    Front Vet Sci; 2024; 11():1391872. PubMed ID: 38957800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
    Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
    Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.
    Cequier A; Romero A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Zaragoza P; Rodellar C; Barrachina L
    Animals (Basel); 2022 Apr; 12(8):. PubMed ID: 35454231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.
    Barrachina L; Cequier A; Romero A; Vitoria A; Zaragoza P; Vázquez FJ; Rodellar C
    Stem Cell Res Ther; 2020 Feb; 11(1):52. PubMed ID: 32028995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
    Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
    Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
    Berglund AK; Schnabel LV
    Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.
    Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Ranera B; Zaragoza P; Martín-Burriel I; Rodellar C
    Vet Immunol Immunopathol; 2016 Mar; 171():57-65. PubMed ID: 26964718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response to allogeneic equine mesenchymal stromal cells.
    Kamm JL; Riley CB; Parlane NA; Gee EK; McIlwraith CW
    Stem Cell Res Ther; 2021 Nov; 12(1):570. PubMed ID: 34772445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.
    Schnabel LV; Pezzanite LM; Antczak DF; Felippe MJ; Fortier LA
    Stem Cell Res Ther; 2014 Jan; 5(1):13. PubMed ID: 24461709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.
    Rowland AL; Miller D; Berglund A; Schnabel LV; Levine GJ; Antczak DF; Watts AE
    Stem Cells Transl Med; 2021 May; 10(5):694-710. PubMed ID: 33369287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Chondrogenic Mesenchymal Stromal Cells Alter Helper T Cell Subsets in CD4+ Memory T Cells.
    Kiernan CH; Asmawidjaja PS; Fahy N; Witte-Bouma J; Wolvius EB; Brama PAJ; Lubberts E; Farrell E
    Tissue Eng Part A; 2020 May; 26(9-10):490-502. PubMed ID: 31797740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.
    Ranera B; Antczak D; Miller D; Doroshenkova T; Ryan A; McIlwraith CW; Barry F
    Equine Vet J; 2016 Mar; 48(2):253-60. PubMed ID: 25582202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.
    Berglund AK; Fisher MB; Cameron KA; Poole EJ; Schnabel LV
    Front Vet Sci; 2017; 4():84. PubMed ID: 28660198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.
    Kol A; Wood JA; Carrade Holt DD; Gillette JA; Bohannon-Worsley LK; Puchalski SM; Walker NJ; Clark KC; Watson JL; Borjesson DL
    Stem Cell Res Ther; 2015 Apr; 6(1):73. PubMed ID: 25888916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.
    Barrachina L; Remacha AR; Romero A; Vitoria A; Albareda J; Prades M; Roca M; Zaragoza P; Vázquez FJ; Rodellar C
    BMC Vet Res; 2018 Aug; 14(1):241. PubMed ID: 30119668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties.
    Berglund AK; Long JM; Robertson JB; Schnabel LV
    Front Cell Dev Biol; 2021; 9():628382. PubMed ID: 33614658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.
    Berglund AK; Fortier LA; Antczak DF; Schnabel LV
    Stem Cell Res Ther; 2017 Dec; 8(1):288. PubMed ID: 29273086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated intra-articular administration of equine allogeneic peripheral blood-derived mesenchymal stem cells does not induce a cellular and humoral immune response in horses.
    Van Hecke L; Magri C; Duchateau L; Beerts C; Geburek F; Suls M; Da Dalt L; Patruno M; Saunders J; Broeckx SY; Depuydt E; Spaas JH
    Vet Immunol Immunopathol; 2021 Sep; 239():110306. PubMed ID: 34365135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.
    Kamm JL; Parlane NA; Riley CB; Gee EK; Dittmer KE; McIlwraith CW
    PLoS One; 2019; 14(11):e0225161. PubMed ID: 31747418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of equine bone marrow derived mesenchymal stem cells increases the expression of immunogenic genes.
    Barrachina L; Remacha AR; Romero A; Zaragoza P; Vázquez FJ; Rodellar C
    Vet Immunol Immunopathol; 2018 Jun; 200():1-6. PubMed ID: 29776607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.